• PCN20 ACCURATE PREDICTIONS OF LIFE YEAR GAINS FOR IMMUNO-ONCOLOGY THERAPIES IN THE LONG TERM? AN ANALYSIS BASED ON PUBLISHED CHECKMATE 057 NIVOLUMAB DATA

    Nov 1, 2019, 00:00

  • PCN509 REAL-WORLD EVIDENCE ON PATIENTS WITH RELAPSED/REFRACTORY FLT3 MUTATION-POSITIVE ACUTE MYELOID LEUKEMIA IN ITALY

    Nov 1, 2019, 00:00

  • PCN254 CHARACTERISING INDIVIDUALS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER USING ROUTINE LINKED HEALTH DATASETS: A FEASIBILITY STUDY

    Nov 1, 2019, 00:00

  • PBI38 INNOVATIVE ATMPS: MARKET ACCESS AND REIMBURSEMENT DECISIONS IN THE EU5: AVAILABILITY OR NOT, THAT IS THE QUESTION...

    Nov 1, 2019, 00:00

  • PNS176 COMPARISON OF HOSPITAL BED NUMBERS IN EUROPEAN OECD COUNTRIES WITH BISMARCK- AND BEVERIDGE HEALTH CARE MODELS

    Nov 1, 2019, 00:00

  • PCN37 THE BENEFIT OF ADJUVANT CHEMOTHERAPY FOR PATIENTS AGED 75 OR OLDER WITH STAGE III COLON CANCER

    Nov 1, 2019, 00:00

  • PCN301 PATIENT ACCESS TO PERSONALIZED ONCOLOGY MEDICINES IN TURKEY

    Nov 1, 2019, 00:00

  • Cancer - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PRO46 EMICIZUMAB PROPHYLAXIS IS A COST-SAVING OPTION FOR HEMOPHILIA A PATIENTS WITH INHIBITORS IN KOREA: A COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2019, 00:00

  • PCN366 TREATMENT LANDSCAPE AND KEY DRIVERS FOR HTA DECISIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITHOUT EGFR OR ALK ALTERATIONS

    Nov 1, 2019, 00:00

  • PCN320 ADMINISTRATIVE OVERSIGHT SHORTENS WAIT-TIME TO BEGIN RADIOTHERAPY IN THE PUBLIC SYSTEM

    Nov 1, 2019, 00:00

  • PCN287 THE ROLE OF EFFICACY AND EFFECTIVENESS ANALYSES IN HEALTH TECHNOLOGY ASSESSMENTS IN DETERMINING TENDERING RANKS FOR ONCOLOGY DRUGS IN DENMARK NORWAY

    Nov 1, 2019, 00:00

  • PGI3 DEPRESCRIBING OF LONG TERM UTILIZATION OF H2 RECEPTOR ANTAGONISTS AND PROTON PUMP INHIBITORS BASED ON ENDOSCOPIC ANALYSIS

    Nov 1, 2019, 00:00

  • PRS73 POLLEN EXPOSURE AND ASTHMA-RELATED HEALTHCARE RESOURCE UTILIZATION IN CHILDREN WITH ASTHMA: AN ANALYSIS OF PATIENT-LEVEL CLAIMS AND LINKED WEATHER DATA

    Nov 1, 2019, 00:00

  • PCV83 EPIDEMIOLOGY OF STABLE CORONARY ARTERY DISEASE AND OF PERIPHERAL ARTERY DISEASE IN PORTUGAL

    Nov 1, 2019, 00:00

  • PDG63 ASSESMENT OF ACCESS TO INNOVATIVE MEDICINES IN UKRAINE

    Nov 1, 2019, 00:00

  • PIN71 PURSUING ELIMINATION OF HEPATITIS C IN EGYPT: AN ECONOMIC EVALUATION OF A COUNTRY-WIDE PROGRAM AND ITS ASSOCIATED COST EFFECTIVENESS

    Nov 1, 2019, 00:00

  • PND67 IDENTIFICATION AND CHARACTERIZATION OF HIGH DISEASE ACTIVITY RELAPSING REMITTING MULTIPLE SCLEROSIS ADULT PATIENTS BASED ON THE SNIIRAM DATABASE

    Nov 1, 2019, 00:00

  • PUK38 PATTERN OF TREATMENT AND HEALTHCARE COSTS OF SECONDARY HYPERPARATHYROIDISM IN DIALYSIS PATIENTS: A REAL-WORLD EVIDENCE ANALYSIS

    Nov 1, 2019, 00:00

  • Infectious Diseases - Medical Technologies

    Nov 1, 2019, 00:00

  • PCN222 CARFILZOMIB/LENALIDOMIDE/DEXAMETHASONE IN THE SECOND-LINE SETTING FOLLOWED BY DARATUMUMAB/LENALIDOMIDE/DEXAMETHASONE IN THE THIRD-LINE SETTING VERSUS THE OPPOSITE TREATMENT SEQUENCE: A COST COMPARISON STUDY FROM A BRAZILIAN PRIVATE H ...

    Nov 1, 2019, 00:00

  • PNS213 NICE FAST TRACK APPRAISALS: A DESCRIPTIVE OVERVIEW

    Nov 1, 2019, 00:00

  • PGI31 SENSITIVITY OF INCREASING BODY WEIGHT IN PATIENTS WITH COLLITIS ULCEROSA TO TOTAL COST OF TREATMENT

    Nov 1, 2019, 00:00

  • PNS324 A NOVEL APPROACH OF USING GRAPHICAL REPRESENTATION OF EQ-5D-3L DIMENSIONS, LEVELS, AND HEALTH STATES FOR ILLITERATE RESPONDENTS IN VALUATION STUDIES - AN EXAMPLE FROM MOROCCO

    Nov 1, 2019, 00:00

  • PRO135 PROJECT HERCULES: A SYSTEMATIC REVIEW OF THE CONTENT AND STRUCTURAL VALIDITY OF PROS USED TO ASSESS QUALITY OF LIFE IN DUCHENNE MUSCULAR DYSTROPHY (DMD)

    Nov 1, 2019, 00:00

  • PCN35 SURVEILLANCE FOR PATIENTS WITH LI-FRAUMENI SYNDROME

    Nov 1, 2019, 00:00

  • PNS121 PRIVATE HEALTH INSURANCE COLLABORATION WITH PHARMACEUTICAL COMPANIES IN EGYPT

    Nov 1, 2019, 00:00

  • PCN521 THE FINANCIAL IMPACT OF AFATINIB REIMBURSEMENT FOR EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER: THE REAL-WORLD EVIDENCE IN TAIWAN

    Nov 1, 2019, 00:00

  • PCN50 INDIRECT COMPARISON OF PARP INHIBITORS IN OVARIAN CANCER: NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00

  • PRS60 IMPACT OF SLEEP DISTURBANCE ON HEALTH-RELATED QUALITY OF LIFE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): WHAT DO WE KNOW SO FAR?

    Nov 1, 2019, 00:00

  • PIN143 MEASUREMENT OF HEALTH RELATED QUALITY OF LIFE IN TUBERCULOSIS PATIENTS USING SPECIFIC AND GENERIC INSTRUMENTS

    Nov 1, 2019, 00:00

  • PSY56 REAL-WORLD DATA FOR HAEMOPHILIA: A SYSTEMATIC APPROACH TO IDENTIFY AND ASSESS DATA SOURCES

    Nov 1, 2019, 00:00

  • PCN524 EUROPEAN REAL-WORLD TREATMENT PATTERNS OF SYSTEMIC THERAPIES FOR SECOND LINE (2L) HEPATOCELLULAR CARCINOMA (HCC) PATIENTS WHO PREVIOUSLY RECEIVED SORAFENIB

    Nov 1, 2019, 00:00

  • PMS20 COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN BIOLOGIC-EXPERIENCED PATIENTS FROM THE PORTUGUESE PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN110 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF MALIGNANT MELANOMA OF SKIN IN HUNGARY: COST OF ILLNESS PILOT STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PCV131 EVALUATION OF PRESCRIBING TRENDS AND ASSESSMENT OF DRUG RELATED PROBLEMS IN PATIENTS WITH ACUTE CORONARY SYNDROME

    Nov 1, 2019, 00:00

  • PMU139 VALIDITY OF THE SLOVENIAN VERSION OF THE CARERQOL-7D QUESTIONNAIRE AMONG INFORMAL CAREGIVERS IN THE SLOVENIAN GENERAL POPULATION

    Nov 1, 2019, 00:00

  • PCN114 ASSESSMENT OF THE SURVIVAL BENEFIT AND COST IMPACT OF NEW TREATMENTS FOR KEY ANSCLC BIOMARKERS USING THE ITEN MODEL

    Nov 1, 2019, 00:00

  • PND101 AN UPDATE OF A SYSTEMATIC REVIEW: ATTRIBUTE BASED STATED PREFERENCE STUDIES IN MULTIPLE SCLEROSIS PATIENTS

    Nov 1, 2019, 00:00

  • PMU103 A CRITICAL REVIEW FRAMEWORK FOR THE ASSESSMENT OF EUNETHTA METHODOLOGICAL GUIDELINES TO INFORM FUTURE JOINT CLINICAL ASSESSMENTS

    Nov 1, 2019, 00:00

  • PDG18 COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT IN TREATING NAMD IN CHINA

    Nov 1, 2019, 00:00

  • Individual's Health - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCN239 MEDICAL COST OF RITUXIMAB-CONTAINING THERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMA IN JAPAN: R-B IS LESS EXPENSIVE THAN R-CHOP

    Nov 1, 2019, 00:00

  • PNS130 ANALYSIS OF LENGTH OF STAY AND COST OF INPATIENT MEDICAL CARE IN RUSSIAN DRG MODEL IN 2018

    Nov 1, 2019, 00:00

  • PMH13 SYSTEMATIC REVIEW OF UTILITY VALUES USED IN THE PHARMACOECONOMIC EVALUATIONS FOR SCHIZOPHRENIA: IMPLICATIONS ON COST-EFFECTIVENESS RESULTS

    Nov 1, 2019, 00:00

  • PCN247 COST-EFFECTIVENESS OF PERTUZUMAB PLUS TRASTUZUMAB VS TRASTUZUMAB IN NEOADJUVANT SETTING BASED ON THE NEOSPHERE TRIAL IN TURKEY

    Nov 1, 2019, 00:00

  • PIN77 EFFICACY MISAPPLICATION IN VACCINE MODELLING

    Nov 1, 2019, 00:00

  • PCN277 INTER-REGIONAL INEQUALITY IN ITALIAN HEALTHCARE DELIVERY AFFECTS CHOICE OF SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) FOR THE TREATMENT OF HORMONE-RECEPTOR-POSITIVE BREAST CANCER

    Nov 1, 2019, 00:00

  • PNS290 EVIDENCE-BASED VALUE FRAMEWORK FOR THE EVALUATION OF CLINICAL PHARMACY SERVICES

    Nov 1, 2019, 00:00

  • PCN330 A COMPARISON OF HEALTHCARE AND SOCIETAL COSTS OF HOSPITAL-BASED AND HOME-BASED SUBCUTANEOUS INJECTIONS OF TRASTUZUMAB

    Nov 1, 2019, 00:00

  • Medical Devices - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PMH30 COST-UTILITY ANALYSIS OF VORTIOXETINE FOR THE TREATMENT OF MAJOR DEPRESSION DISORDERS IN CHINA

    Nov 1, 2019, 00:00

  • PNS370 METHODS AND CONSIDERATIONS FOR THE DEVELOPMENT, CONTENT VALIDITY TESTING, AND EVALUATION OF PATIENT EDUCATION TOOLS (PETS)

    Nov 1, 2019, 00:00

  • PIN49 BURDEN OF S. AUREUS, E. COLI, K. PNEUMONIAE ASSOTIATED INFECTIONS IN RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PCV66 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF ARTERIAL EMBOLISM AND THROMBOSIS IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PUK35 THE BURDEN OF INCONTINENCE IN A REAL-WORLD DATA ENVIRONMENT - INSIGHTS FROM A DIGITAL PREVENTION COMPANION

    Nov 1, 2019, 00:00

  • PDB35 COST-EFFECTIVENESS OF GLICLAZIDE MR-BASED INTENSIVE GLUCOSE CONTROL VERSUS STANDARD GLUCOSE CONTROL IN TYPE 2 DIABETES MELLITUS. AN ECONOMIC ANALYSIS IN VIETNAM OF THE ADVANCE TRIAL

    Nov 1, 2019, 00:00

  • PNS138 TRANSNATIONAL COLLABORATIONS AMONG DRUG REGULATORY AGENCIES: TRENDS AND FUTURE PERSPECTIVES

    Nov 1, 2019, 00:00

  • PCN327 KEY INTERVALS IN THE PATIENT JOURNEY OF MEN WITH PROSTATE CANCER: EVIDENCE FROM GREECE

    Nov 1, 2019, 00:00

  • PCN180 EQ-5D UTILITY ESTIMATES FROM THE IMPOWER 133 TRIAL OF TECENTRIQ + CARBOPLATIN + ETOPOSIDE VS. CARBOPLATIN + ETOPOSIDE IN FIRST LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)

    Nov 1, 2019, 00:00

  • PCN139 BUDGET IMPACT ANALYSIS OF NILOTINIB AS FIRST LINE TREATMENT OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) WITH HIGH RISK SOKAL SCORE IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00

  • PMD37 EVOLUTION OF UNION EUROPEAN MEDICAL DEVICE REGULATION: PERSPECTIVE WITH THE CLINICAL EVALUATION OF DUAL MOBILITY ACETABULAR CUPS BY THE FRENCH NATIONAL HEALTH TECHNOLOGY ASSESSMENT AGENCY

    Nov 1, 2019, 00:00

  • PUK30 COMPARING SOFTWARE FOR PATIENT-LEVEL SIMULATION: REPLICATING A MODEL OF HYPERPHOSPHATAEMIA IN CHRONIC KIDNEY DISEASE

    Nov 1, 2019, 00:00

  • PIH46 COST EFFECTIVENESS ANALYSIS FOR A MULTI-FACTORIAL INTERVENTION FOR ELDERLY INPATIENTS WITH DELIRIUM, UTILIZING REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PCN96 COST-EFFECTIVENESS OF TREATMENT SEQUENCES FOR BRAF WILD-TYPE METASTATIC MELANOMA IN REAL LIFE IN FRANCE

    Nov 1, 2019, 00:00

  • PCN486 REGULATORY SUCCESS IN LABELLING HRQOL AND SYMPTOMS FOR NSCLC THERAPIES

    Nov 1, 2019, 00:00

  • PNS6 SYSTEMATIC LITERATIVE REVIEW AND QUALITATIVE ANALYSIS ASSESSING EFFICACY AND SAFETY OF INTERVENTIONS IN ACTINIC KERATOSIS

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PDB43 COST COMPARISON OF GLICAZIDE MODIFIED-RELEASE AND GENERIC GLICLAZIDE IN PREVENTING END STAGE RENAL DISEASE IN TYPE 2 DIABETES MELLITUS IN THE PUBLIC SECTOR OF MALAYSIA

    Nov 1, 2019, 00:00

  • PNS302 IMPROVING THE PERFORMANCE OF PATIENT-LEVEL SIMULATION MODELS USING MULTI-THREADING AND SINGLE INSTRUCTION MULTIPLE DATA (SIMD) OPERATIONS

    Nov 1, 2019, 00:00

  • PCN460 SYSTEMATIC LITERATURE REVIEW FOR UTILITY DATA IN ACUTE MYELOID LEUKEMIA

    Nov 1, 2019, 00:00

  • PCN485 PATIENT-REPORTED OUTCOMES AND THEIR RELATIONSHIP WITH CLINICAL OUTCOMES IN PATIENTS WITH FLT3-MUTATED (FLT3 MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL STUDY

    Nov 1, 2019, 00:00

  • PNS35 MULTI-NATIONAL NORDIC PHARMACOEPIDEMIOLOGIC STUDIES: OPPORTUNITIES AND CHALLENGES

    Nov 1, 2019, 00:00

  • PIN74 A NEW WAY TO INFORM DECISION-MAKER AND ENHANCE VACCINATION PROGRAMS IN COUNTRIES WITH LIMITED BUDGETS: THE CASE OF SERBIA

    Nov 1, 2019, 00:00

  • PBI9 SYSTEMATIC LITERATURE REVIEW OF NMAS AND POPULATION ADJUSTED INDIRECT COMPARISONS OF BIOLOGICAL TREATMENTS IN MODERATE-TO-SEVERE PSORIASIS

    Nov 1, 2019, 00:00

  • PNS266 DIFFERENT INTERPRETATION OF ADDITIONAL EVIDENCE FOR HTA BY THE COMMISSIONED HTA BODY AND THE COMMISSIONING DECISION MAKER IN GERMANY: WHENEVER IQWIG AND FEDERAL JOINT COMMITTEE DISAGREE

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PCN467 THE HUMANISTIC BURDEN OF MULTIPLE MYELOMA IN NEWLY DIAGNOSED PATIENTS: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PGI30 THE MEDICAL COSTS OF INFLAMMATORY BOWEL DISEASE IN RUSSIA FROM A PUBLIC PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PIH29 SELF- MEDICATION: ASSESSMENT OF PRACTICES AMONG PREGNANT WOMEN

    Nov 1, 2019, 00:00

  • PCV104 A SYSTEMATIC REVIEW OF ORGANISATIONAL AND SERVICE SPECIFICATION RECOMMENDATIONS FOR CENTRES PROVIDING PERCUTANEOUS CORONARY INTERVENTIONS

    Nov 1, 2019, 00:00

  • Cancer - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PDB15 THE COST OF HYPOGLYCAEMIA IN TYPE 2 DIABETES MELLITUS IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PNS368 THE EVOLVING ROLE OF PATIENT ADVOCACY IN DRUG APPRAISAL AND COMMISSIONING: PERSPECTIVES FROM ENGLAND

    Nov 1, 2019, 00:00

  • PCV6 BURDEN OF MORTALITY IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION - A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PNS20 RECENT ADVANCES IN THE EUROPEAN CROSS-BORDER COLLABORATIONS IN JOINT DRUG PROCUREMENT LANDSCAPE

    Nov 1, 2019, 00:00

  • PCN146 VALIDATION OF PREDICTED SURVIVAL ESTIMATES FROM PREVIOUS DATA CUTS OF THE PHASE III CHECKMATE 025 STUDY IN ADVANCED RENAL CELL CARCINOMA

    Nov 1, 2019, 00:00

  • PIH40 ASSESSING HEALTH DISPARITY IN THE ELDERLY POPULATION WITH DIFFERENT ECONOMIC STATUS IN SOUTH KOREA: FOCUSING ON HIP FRACTURE

    Nov 1, 2019, 00:00

  • PMH32 THE ECONOMIC BURDEN OF ALCOHOL CONSUMPTION IN THE CZECH REPUBLIC

    Nov 1, 2019, 00:00

  • PMS78 CANADIAN REAL-WORLD EVIDENCE ON EPIDEMIOLOGY, OUTCOMES AND ECONOMICS OF MODERATE-TO-SEVERE OSTEOARTHRITIS: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • Surgery - Medical Technologies

    Nov 1, 2019, 00:00

  • PDG74 AN ANALYSIS OF RESTRICTED RECOMMENDATIONS BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Nov 1, 2019, 00:00

  • PCN373 RECENT COST PER QALY TRENDS OF NON-HAEMATOLOGICAL CANCERS ASSESSMENT AT NICE

    Nov 1, 2019, 00:00

  • PCN15 PROPHYLAXIS FOR BICALUTAMIDE-INDUCED GYNECOMASTIA: A NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00

  • PGI12 COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE IN BIOLOGIC NAIVE PATIENTS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM ...

    Nov 1, 2019, 00:00

  • PCN16 ASSESSMENT OF THE QUALITY OF LIFE, PHYSICAL ACTIVITY, DEPRESSION AND ANXIETY OF PATIENTS UNDER ONCOLOGY CARE

    Nov 1, 2019, 00:00

  • PBI37 BIOSIMILAR INTERCHANGEABILITY, SUBSTITUTION AND SWITCHING: AN OVERVIEW OF 5 EUROPEAN MEMBER STATES AND THE UNITED STATES

    Nov 1, 2019, 00:00

  • PCV50 COST-EFFECTIVENESS OF TARGETED SCREENING USING A MACHINE LEARNING RISK PREDICTION TOOL FOR THE IDENTIFICATION OF PATIENTS WITH ATRIAL FIBRILLATION

    Nov 1, 2019, 00:00

  • PRO117 ACCESS TO ORPHAN DRUGS IN THE UNITED KINGDOM: A REVIEW OF NICE DECISIONS FROM 2017-2018

    Nov 1, 2019, 00:00

  • PCV73 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS WARFARIN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION IN THE JAPANESE HEALTHCARE SETTING

    Nov 1, 2019, 00:00

  • PND66 ASSESSING THE POTENTIALLY INAPPROPRIATE USE OF ACETYLCHOLINESTERASE INHIBITORS IN ELDERLY PATIENTS WITH PARKINSON DISEASE USING KOREA NATIONAL HEALTH INSURANCE CLAIMS DATA

    Nov 1, 2019, 00:00

  • PCN68 BRENTUXIMAB VEDOTIN FOR CONSOLIDATION THERAPY AFTER ASCT IN CD30+ HODGKIN'S LYMPHOMA: A SUSTAINABLE PHARMACEUTICAL EXPENDITURE FOR THE ITALIAN NATIONAL HEALTH SERVICE

    Nov 1, 2019, 00:00

  • PND68 ASSOCIATION BETWEEN HEPATITIS C VIRUS INFECTION AND PARKINSON'S DISEASE IN PATIENTS FOLLOWED BY GENERAL PRACTITIONERS IN GERMANY

    Nov 1, 2019, 00:00

  • PCN293 POST-PROGRESSION ENDPOINTS IN ONCOLOGY TRIALS: CURRENT CLINICAL AND REIMBURSEMENT PERSPECTIVES

    Nov 1, 2019, 00:00

  • PND39 A COST-EFFECTIVENESS ANALYSIS OF PREGABALIN VS. DULOXETINE IN THE TREATMENT OF FIBROMYALGIA IN CHINA

    Nov 1, 2019, 00:00

  • Cancer - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PBI14 COST-EFFECTIVENESS OF SECUKINUMAB VERSUS OTHER BIOLOGICS AND APREMILAST IN THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS: A SPANISH PERSPECTIVE

    Nov 1, 2019, 00:00

  • PR3 HOME-BASED ASSESSMENT OF PATIENT REPORTED OUTCOME MEASURES USING A SMARTPHONE APP PLATFORM: A FEASIBILITY STUDY

    Nov 1, 2019, 00:00

  • PMS21 PRELIMINARY RESULTS OF A COST-UTILITY ANALYSIS OF A FRACTURE LIAISON SERVICE BASED ON HEALTH SERVICES INDICATORS

    Nov 1, 2019, 00:00

  • PGI23 COST OF INFLAMMATORY BOWEL DISEASE MANAGEMENT IN THE KINGDOM OF SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PSU15 COST-EFFECTIVENESS OF SHOULDER ARTHROPLASTY: A PROSPECTIVE STUDY USING REAL-WORLD DATA FROM SWITZERLAND

    Nov 1, 2019, 00:00

  • PCN85 COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBASTIC LEUKAEMIA, FROM A GREEK SOCIAL SECURITY SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PNS229 COMPARATIVE ANALYSIS OF TRANSPARENCY COMMITTEE OPINION CONCERNING THE ADDED MEDICAL BENEFIT OBTAINED BY DRUGS AVAILABLE THROUGH EARLY ACCESS PROGRAM VS THE OTHERS

    Nov 1, 2019, 00:00

  • PMU52 ANALYSIS OF THE REIMBURSEMENT DECISIONS MADE BY THE INTERMINISTERIAL PRICE COMMISSION FOR MEDICINES IN SPAIN

    Nov 1, 2019, 00:00

  • PCN481 METHODOLOGICAL ASPECTS OF HEALTH-RELATED QUALITY OF LIFE MEASUREMENT IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER IN CLINICAL TRIALS: A SYSTEMATIC REVIEW.

    Nov 1, 2019, 00:00

  • Mental Health - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PRO69 EPIDEMIOLOGICAL MODEL TO SUPPORT ORPHAN DESIGNATION DECISIONS: A DICE SIMULATION STUDY

    Nov 1, 2019, 00:00

  • PCV99 UNDERSTANDING POST DISCHARGE MANAGEMENT AFTER AN ACUTE MYOCARDIAL INFARCTION IN ITALY: REGIONAL PATHWAYS AND OUTCOME INDEX

    Nov 1, 2019, 00:00

  • PNS392 THE ROLE OF PATIENTS IN THE UPTAKE OF PHARMACEUTICAL PRODUCTS BY PATIENTS AS PERCEIVED BY PROFESSIONALS

    Nov 1, 2019, 00:00

  • PCN255 ESTIMATION OF THE POTENTIAL IMPACT OF THE FRENCH CRC SCREENING PROGRAM BASED ON REAL-WORLD PARTICIPATION RATES

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Organizational Practices

    Nov 1, 2019, 00:00

  • PIN14 HEALTH UTILITY ESTIMATES FOR CONGENITAL CYTOMEGALOVIRUS DISEASE: CONCEPTUAL DESIGN CONSIDERATIONS

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PND65 FILLING THE GAP IN MS; UNIQUE IDENTIFICATION OF PREVALANCE TREATMENT OF SPMS PATIENTS IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PDB69 ECONOMIC BURDEN OF TYPE 2 DIABETES (T2D) IN EMERGING AND ESTABLISHED MARKETS: DATA FROM THE G15 REVIEW

    Nov 1, 2019, 00:00

  • PRO3 TREATMENT PATTERNS AND OUTCOMES ASSOCIATED WITH THE USE OF PONATINIB IN CLINICAL PRACTICE: A QUALITATIVE SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PCV57 STUDY ON THE ATTRIBUTABLE COSTS OF VENOUS THROMBOEMBOLISM AND BLEEDINGS IN DENMARK. COMPARISON OF THE DIFFERENCE-IN-DIFFERENCE AND THE DIFFERENCE-IN-ACTUAL-COSTS METHODS

    Nov 1, 2019, 00:00

  • PCN454 A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ELOTUZUMAB/POMALIDOMIDE/DEXAMETHASONE (EPD) VERSUS PANOBINOSTAT/BORTEZOMIB/DEXAMETHASONE (PANO-VD) AND DARATUMUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

    Nov 1, 2019, 00:00

  • Drugs Generics - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCN248 COST-UTILITY ANALYSIS OF FIRST-LINE THERAPY FOR ADVANCED AND METASTATIC PANCREATIC CANCER IN JAPAN.

    Nov 1, 2019, 00:00

  • Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions [Editor's Choice]

    Nov 1, 2019, 00:00

  • PDB38 COST OF ANTI-DIABETIC MEDICATIONS AMONG TYPE II DIABETES MELLITUS PATIENTS: A CROSS-SECTIONAL STUDY IN SOUTH INDIA

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCN474 MAPPING PATIENT INVOLVEMENT IN NICE APPRAISALS OF ONCOLOGY PRODUCTS

    Nov 1, 2019, 00:00

  • PDG107 DRUG SURVIVAL OF BIOLOGICAL THERAPIES FOR ANKYLOSING SPONDYLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REAL-WORLD EVIDENCE

    Nov 1, 2019, 00:00

  • PNS150 CONDITIONAL MARKETING AUTHORISATION FOR NOVEL TREATMENTS: A LANDSCAPE ASSESSMENT OF EXPEDITED PATHWAYS OUTSIDE US AND EU

    Nov 1, 2019, 00:00

  • PRO123 DEVELOPING AN EVIDENCE GENERATION PLAN FOR THE VALUE STORY OF AN ORPHAN DRUG

    Nov 1, 2019, 00:00

  • PUK3 TREATMENT EFFECTS IN SECONDARY HYPERPARATHYROIDISM IN NON-DIALYSIS CHRONIC KIDNEY DISEASE: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN195 COST COMPARISON BETWEEN LEUPROLIDE 3-MONTH FORMULATION AND GOSERELIN 1-MONTH FORMULATION AS ADJUVANT ENDOCRINE THERAPY IN POST-MASTECTOMY, PREMENOPAUSAL WOMEN WITH EARLY-STAGE, ESTROGEN RECEPTOR-POSITIVE BREAST CANCER WHO ARE AT MODE ...

    Nov 1, 2019, 00:00

  • PND36 10-YEAR COST-EFFECTIVENESS ANALYSES OF FREMANEZUMAB COMPARED TO NO TREATMENT AS A PREVENTIVE TREATMENT IN CHRONIC AND EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS

    Nov 1, 2019, 00:00

  • PCN238 IS POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE-RITUXIMAB COST-EFFECTIVE FOR PATIENTS IN THE UNITED STATES WITH TRANSPLANT-INELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA?

    Nov 1, 2019, 00:00

  • PRO29 COST-EFFECTIVENESS OF VORETIGENE NEPARVOVEC FOR VISION LOSS DUE TO BIALLELIC RPE65-MEDIATED INHERITED RETINAL DISEASE IN A DANISH SETTING

    Nov 1, 2019, 00:00

  • PDG25 ECONOMIC BURDEN OF OPIOID ABUSE IN THE USA

    Nov 1, 2019, 00:00

  • PCN305 FUNDING TRENDS FOR IN-HOSPITAL DRUGS: GERMAN NUB ANALYSIS

    Nov 1, 2019, 00:00

  • PCN336 PARALLEL SCIENTIFIC ADVICE FROM NICE AND CADTH: WOULD ONE SUBMISSION FIT ALL?

    Nov 1, 2019, 00:00

  • PCN165 A GERMAN COST ANALYSIS OF TRIPLET REGIMENS FOR RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS

    Nov 1, 2019, 00:00

  • PMD47 BREAKAGE OF INTRAMEDULLARY NAILING IN TROCHANTERIC, INTERTROCHANTERIC AND SUBTROCHANTERIC FEMUR FRACTURES

    Nov 1, 2019, 00:00

  • PCN67 COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY IN PORTUGAL

    Nov 1, 2019, 00:00

  • PDG76 IN VITRO DATA AS COMPLEMENTARY EVIDENCE SOURCE FOR THE ASSESSMENT OF ANTIBIOTICS IN THE GERMAN BENEFIT ASSESSMENT?

    Nov 1, 2019, 00:00

  • PCV117 DESIGNING THE NEXT TRIAL FROM NETWORK META-ANALYSES USING SIMULATION-BASED ASSURANCE CALCULATIONS

    Nov 1, 2019, 00:00

  • PNS88 THE "REHAB MAP” FOR INTERACTIVE PLANNING OF AMBULATORY REHABILITATION SERVICES

    Nov 1, 2019, 00:00

  • PMU62 ASSESSING WHETHER PRODUCTS NEED TO BE COST-SAVING IN ORDER TO GAIN ACCELERATED ACCESS COLLABORATIVE RAPID UPTAKE STATUS IN NHS ENGLAND

    Nov 1, 2019, 00:00

  • PSS20 CONFIRMATION OF THE MEASUREMENT PROPERTIES OF THE NATIONAL EYE INSTITUTE VISUAL FUNCTIONING QUESTIONNAIRE 28 ITEM RASCH-BASED SCORING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

    Nov 1, 2019, 00:00

  • PCV54 THE HEALTHCARE MANAGEMENT OF PATIENTS WITH THE CORONARY AND PERIPHERAL ARTERIAL DISEASES

    Nov 1, 2019, 00:00

  • PCV78 BURDEN OR ATRIAL FIBRILLATION AND BUDGET IMPACT OF DABIGATRAN IN ALGERIA

    Nov 1, 2019, 00:00

  • PMD15 COST EFFECTIVENESS ANALYSIS OF STANDARD AND PREMIUM INTRAOCULAR LENSES IMPLEMENTED IN THE TREATMENT OF CATARACT UNDER DIFFERENT INSURANCE SCHEMES IN EGYPT

    Nov 1, 2019, 00:00

  • PCN264 ESTIMATING THE BURDEN OF SALIVARY GLAND CANCER IN NORDIC COUNTRIES: A PREDICTIVE ANALYSIS USING TIME SERIES ANALYSIS METHODS

    Nov 1, 2019, 00:00

  • PCN75 EPIDEMIOLOGY, MORTALITY AND STANDARD OF CARE IN ADVANCED BREAST CANCER - A MULTIPLE COUNTRY ANALYSIS

    Nov 1, 2019, 00:00

  • PNS275 SHOULD LIFECYCLE PRICING BE CONSIDERED IN HTA? PRACTICAL CONSIDERATIONS FOR INCORPORATION INTO HTA POLICY

    Nov 1, 2019, 00:00

  • PIN86 CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH VARYING COVERAGE OF VARICELLA VACCINATION STRATEGIES IN SWITZERLAND

    Nov 1, 2019, 00:00

  • PCN458 ATTITUDE TOWARDS PARTICIPATION ON BREAST CANCER SCREENING AND THE ASSESSMENT OF INFLUENCING FACTORS AMONG 45-65 YEARS OLD WOMEN

    Nov 1, 2019, 00:00

  • PBI88 ASSESSMENT OF PATIENTS AFFECTED BY RHEUMATOID ARTHRITIS ELIGIBLE FOR BIOLOGIC AGENTS

    Nov 1, 2019, 00:00

  • PCN87 COST-EFFECTIVNESS ANALYSIS OF DABRAFENIB PLUS TRAMETINIB AS ADJUVANT TREATMENT FOR BRAF V600 MUTATION-POSITIVE MELANOMA AFTER SURGICAL RESECTION IN CANADA- A SOCIETAL PERSPECTIVE

    Nov 1, 2019, 00:00

  • PNS112 PHARMACIST’S PRIVILEGE IN SAUDI ARABIA: PHARMACIST PRESCRIBING AND THERAPEUTIC INTERCHANGE

    Nov 1, 2019, 00:00

  • PCN494 POTENTIAL USE OF ARTIFICIAL INTELLIGENCE TO ANALYZE DATA EXTRACTED FROM ELECTRONIC HEALTH RECORDS FOR DECISION ANALYTIC MODELS

    Nov 1, 2019, 00:00

  • PCN173 ACCOUNTING FOR TIME-DEPENDENT HEALTH STATE MEMBERSHIP IN BUDGET IMPACT ANALYSIS - CASE STUDY IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PNS361 THE TSQM: 15 YEARS OF USE

    Nov 1, 2019, 00:00

  • PIN145 PATIENT PREFERENCES TOWARDS DRUG TREATMENT OF CHRONIC HEPATITIS B - A DISCRETE CHOICE EXPERIMENT IN GERMANY

    Nov 1, 2019, 00:00

  • PCN364 REIMBURSEMENT OF CAR-T CELL THERAPY IN THE UK, A STEP TOWARDS MORE PERSONALISED CANCER TREATMENT

    Nov 1, 2019, 00:00

  • PCN32 COMPARATIVE EFFICACY OF PEMBROLIZUMAB PLUS AXITINIB (P+A) VERSUS FIRST-LINE SYSTEMIC THERAPIES FOR ELDERLY PATIENTS WITH ADVANCED/METASTATIC RCC (MRCC): A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00

  • PDB112 EXPERIENCES OF PATIENTS WITH TYPE 2 DIABETES MELLITUS PATIENTS IN THE KINGDOM OF SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PRO9 A SYSTEMATIC REVIEW OF THE CLINICAL BURDEN OF IDIOPATHIC MULTICENTRIC CASTLEMAN'S DISEASE

    Nov 1, 2019, 00:00

  • PCN434 THE EFFECT MODIFICATION PROBLEM: USING STRATIFIED MATCHING ADJUSTED INDIRECT COMPARISON TO EVADE MISLEADING INTERPRETATIONS OF THE TREATMENT EFFECT

    Nov 1, 2019, 00:00

  • PDB26 THE BURDEN OF SEVERE HYPOPARATHYROIDISM IN GERMANY - A CLAIMS DATABASE ANALYSIS

    Nov 1, 2019, 00:00

  • What Is Next for Patient Preferences in Health Technology Assessment? A Systematic Review of the Challenges

    Nov 1, 2019, 00:00

  • PCN350 CLINICAL AND ECONOMIC ASSESSMENT OF THE IMPORTANCE OF SUPPORTIVE THERAPY IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PNS250 CADTH PARALLEL SCIENTIFIC ADVICE PROGRAMS WITH NICE AND HEALTH CANADA

    Nov 1, 2019, 00:00

  • PDG75 TRENDS IN THE USE OF PATIENT ACCESS SCHEMES AND COMMERCIAL ACCESS ARRANGEMENTS IN HEALTH TECHNOLOGY ASSESSMENTS (HTA) BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Nov 1, 2019, 00:00

  • PBI28 COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE

    Nov 1, 2019, 00:00

  • PR2 FATIGUE: ITS USE ACROSS TRIALS FOR MULTIPLE CONDITIONS: REGULATORY SUCCESS

    Nov 1, 2019, 00:00

  • PMD8 ESTIMATING THE POTENTIAL CASES OF BLINDNESS AND COSTS AVOIDED AND IN REALLOCATING HEALTHCARE RESOURCE UTILIZATION FROM TREATING POSTERIOR CAPSULAR OPACIFICATION TO NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

    Nov 1, 2019, 00:00

  • PCV81 CURRENT TRENDS IN LIPID LOWERING THERAPY USE IN GERMANY

    Nov 1, 2019, 00:00

  • PCN174 BUDGET IMPACT OF LEUPROLIDE ACETATE 3-MONTHLY DEPOT FORMULATIONS FOR THE MANAGEMENT OF PATIENTS WITH ADVANCED AND METASTATIC PROSTATE CANCER IN GREECE

    Nov 1, 2019, 00:00

  • PNS126 NEW DRUG BUDGET AND REIMBURSEMENT POLICY IN TAIWAN

    Nov 1, 2019, 00:00

  • PSU44 MANAGEMENT OF PERIPROCEDURAL THROMBOTIC AND BLEEDING EVENTS IN PERCUTANEOUS CORONARY INTERVENTIONS IN EUROPE: PILOT SURVEY OF TREATMENT STRATEGIES AND HOSPITAL RESOURCES USE

    Nov 1, 2019, 00:00

  • PCN184 ECONOMIC EVALUATION OF CHECKPOINT INHIBITORS FOR THE TREATMENT OF ADVANCED MELANOMA IN THE IRISH HEALTHCARE SETTING

    Nov 1, 2019, 00:00

  • Surgery - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PIT15 INTRAMEDULLARY NAILING OF HUMERAL FRACTURES: PATIENT CHARACTERISTICS ASSOCIATED WITH POSTOPERATIVE COMPLICATIONS

    Nov 1, 2019, 00:00

  • PCN47 REAL WORLD EVIDENCE OF DARATUMUMAB IN MULTIPLE MYELOMA

    Nov 1, 2019, 00:00

  • PRO11 FACTORS ASSOCIATED WITH BLEEDING EXPERIENCE IN HEMOPHILIA A PATIENTS IN SOUTH KOREA

    Nov 1, 2019, 00:00

  • PMS51 TRAJECTORIES OF FOLLOW-UP COMPLIANCE AND THEIR PREDICTORS IN A FRACTURE LIAISON SERVICE

    Nov 1, 2019, 00:00

  • PMU34 COMPARATIVE ANALYSIS OF DISABILITY ADJUSTED LIFE YEARS FROM ADVERSE EFFECTS OF MEDICAL TREATMENT IN UKRAINE AND OTHER COUNTRIES

    Nov 1, 2019, 00:00

  • PCN480 RELEVANCE OF SELECTED PATIENT-REPORTED OUTCOME (PRO) MEASURES IN EPSTEIN-BARR VIRUS ASSOCIATED (EBV+) POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD) PATIENTS

    Nov 1, 2019, 00:00

  • AI4 GENERAL PAIRWISE COMPARISONS TO SUPPORT QUANTITATIVE MULTIPLE CRITERIA DECISION ANALYSIS

    Nov 1, 2019, 00:00

  • PSY45 PATIENT-REPORTED OUTCOMES USED IN CLINICAL TRIALS OF SYSTEMIC LUPUS ERYTHEMATOSUS: A REVIEW OF SUITABILITY FOR FDA LABELLING CLAIMS

    Nov 1, 2019, 00:00

  • PND50 ECONOMIC BURDEN OF ALZHEIMER'S DISEASE DEMENTIA IN JAPAN

    Nov 1, 2019, 00:00

  • PRS67 GENDER DIFFERENCES IN ASTHMA PERCEPTION AND IMPACT ON QUALITY OF LIFE: A POST-HOC ANALYSIS OF THE PROXIMA OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PCN344 ADDITION OF PERTUZUMAB TO TRASTUZUMAB-BASED ADJUVANT THERAPY IN HIGH-RISK HER2-POSITIVE EARLY BREAST CANCER: A GRADE-BASED ANALYSIS FROM THE PHASE III APHINITY TRIAL

    Nov 1, 2019, 00:00

  • PNS87 IMPACT OF SELF SUSTAINABLE SYSTEM FOR SAFE DRUG DISPOSAL: A FOLLOW UP STUDY

    Nov 1, 2019, 00:00

  • PNS384 HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASURED BY PROMIS PREFERENCE SCORE (PROPR) IN THE GENERAL POPULATION OF THE UNITED KINGDOM, FRANCE, AND GERMANY

    Nov 1, 2019, 00:00

  • PDB106 DOES MOBILE HEALTH LIVE UP TO EXPECTATIONS? EXPLORING REAL-WORLD EXPERIENCES IN PATIENTS WITH DIABETES

    Nov 1, 2019, 00:00

  • PMU91 CURRENT TREND OF UTILITY VALUES IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) TECHNOLOGY APPRAISAL GUIDANCE

    Nov 1, 2019, 00:00

  • PDB33 COST-EFFECTIVENESS OF THE PDM-PROVALUE STUDY PROGRAM IN INSULIN-TREATED PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM THE GERMAN STATUTORY HEALTHCARE PERSPECTIVE

    Nov 1, 2019, 00:00

  • PNS197 WAITING TIMES FOR HEALTH CARE SERVICES IN HUNGARY - RESULTS OF A REPRESENTATIVE POPULATION SURVEY

    Nov 1, 2019, 00:00

  • PMD60 AN INNOVATIVE REUSABLE ELECTRONIC INJECTION DEVICE FOR CERTOLIZUMAB PEGOL: RESULTS FROM A PILOT MARKET RESEARCH STUDY EXAMINING PATIENT PREFERENCE AND SATISFACTION

    Nov 1, 2019, 00:00

  • PCN469 DISEASE SPECIFIC PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS FOR HEMATOLOGIC MALIGNANCIES (HM)

    Nov 1, 2019, 00:00

  • PMH25 ASSOCIATION OF ADOLESCENT DEPRESSION WITH EARNINGS IN ADULTHOOD

    Nov 1, 2019, 00:00

  • PRO26 THE NICE APPRAISAL OF BUROSUMAB FOR THE TREATMENT OF XLH: EVALUATING THE LIFELONG OUTCOMES AND COST-EFFECTIVENESS OF CORRECTING DEFORMITY WHEN TREATING CHILDREN AND ADOLESCENTS WITH A GROWING SKELETON

    Nov 1, 2019, 00:00

  • PGI26 A BUDGET IMPACT ANALYSIS OF RIFAXIMIN FOR TREATMENT OF HEPATIC ENCEPHALOPATHY IN TERTIARY HOSPITAL,RIYADH, SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PND118 PATIENTS WITH CHRONIC PAIN DISORDERS: PREFERENCE OF EPRO SCREEN DISPLAY AND FEATURES

    Nov 1, 2019, 00:00

  • PSY10 PRIMARY SJOGREN'S SYNDROME: A RETROSPECTIVE COHORT STUDY OF BURDEN OF ILLNESS IN SWEDEN

    Nov 1, 2019, 00:00

  • PCN22 BURDEN OF BRAIN METASTASES (BM) IN ALK+ NON-SMALL CELL LUNG CANCER (ALK+ NSCLC) TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR)

    Nov 1, 2019, 00:00

  • PCN340 FAST CHANGING APPROPRIATE COMPARATORS IN GERMAN AMNOG BENEFIT ASSESSMENTS IN MULTIPLE MYELOMA

    Nov 1, 2019, 00:00

  • PSY15 COMPARISONS OF COSTS RELATED TO THE INITIATION OF TAPENTADOL OR OXYCODONE TREATMENT IN SPANISH PATIENTS SUFFERING FROM SEVERE NON-MALIGNANT PAIN

    Nov 1, 2019, 00:00

  • PRO45 NATIONAL BURDEN OF HEMOPHILIA A IN TURKEY

    Nov 1, 2019, 00:00

  • PCV86 ASSOCIATION OF ADHERENCE AND TREATMENT INTENSITY OF LIPID-LOWERING THERAPY WITH CARDIOVASCULAR OUTCOMES AND ALL-CAUSE MORTALITY IN POST-MI PATIENTS IN GERMANY.

    Nov 1, 2019, 00:00

  • PNS3 COMPARISON OF FIVE METHODS FOR DOWNLOADING CONFERENCE ABSTRACTS: A CASE STUDY

    Nov 1, 2019, 00:00

  • PBI31 COST-EFFECTIVENESS COMPARISON OF RISANKIZUMAB AND USTEKINUMAB FOR THE TREATMENT OF SEVERE PSORIASIS

    Nov 1, 2019, 00:00

  • PMD24 ECONOMIC EVALUATION OF CENTRIFUGAL AND MEMBRANE THERAPEUTIC PLASMA EXCHANGE IN TAIWAN

    Nov 1, 2019, 00:00

  • PDG14 COST-UTILITY OF DALBAVANCIN VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH ABSSSI IN ITALY

    Nov 1, 2019, 00:00

  • PMU84 DRUG DECISION-MAKING PATHWAYS IN ENGLAND: CURRENT PROCESSES AND THE POTENTIAL IMPACT OF NICE CHANGES

    Nov 1, 2019, 00:00

  • PGI37 REDUCTION IN CO-THERAPY COSTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH BIOLOGICAL DRUGS

    Nov 1, 2019, 00:00

  • PNS63 WILLINGNESS TO PAY FOR HEALTH INSURANCE USING THE CONTINGENT VALUATION METHOD: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PDB32 WOULD A COHORT-LEVEL APPROACH TO COST-EFFECTIVENESS MODELLING HAVE LED TO A DIFFERENT DECISION IN AN IMPORTANT NICE APPRAISAL FOR OBESITY PATIENTS?

    Nov 1, 2019, 00:00

  • PMH64 PHARMACOTHERAPY COST AND PRESCRIBING PRACTICE FOR PSYCHOTIC DISORDERS IN BULGARIA

    Nov 1, 2019, 00:00

  • PNS178 PRIVATE HEALTH INSURANCE PERCEPTION OF THEIR ROLE AFTERWARD UNIVERSAL HEALTH INSURANCE IN EGYPT

    Nov 1, 2019, 00:00

  • PMU40 NEWLY DIAGNOSED DEPRESSION AND DEPRESSION SEVERITY AMONG WOMEN WITH INCIDENT BREAST CANCER

    Nov 1, 2019, 00:00

  • PNS143 PRIORITIZATION OF DRUGS FOR REIMBURSEMENT IN THE MALTESE HEALTH SYSTEM.

    Nov 1, 2019, 00:00

  • PRO97 VALUE ASSESSMENT FRAMEWORKS FOR ORPHAN DRUGS: A COMPARATIVE ANALYSIS ACROSS EUROPEAN JURISDICTIONS

    Nov 1, 2019, 00:00

  • PMU39 CERVICAL CANCER PREVENTION THROUGH HUMAN PAPILLOMAVIRUS (HPV) VACCINATION: A CASE STUDY IN ETHIOPIA

    Nov 1, 2019, 00:00

  • PSY49 THE JOURNEY OF THALASSAEMIA PATIENT IN SEEKING TREATMENT IN MALAYSIAN HEALTHCARE

    Nov 1, 2019, 00:00

  • PNS73 WHAT IS THE VALUE FOR A QALY IN FRANCE?

    Nov 1, 2019, 00:00

  • PCN101 COST-EFFECTIVENESS ANALYSIS OF TORIPALIMAB VERSUS PEMBROLIZUMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA IN CHINA

    Nov 1, 2019, 00:00

  • PMD13 COST-UTILITY ANALYSIS OF ISTENT INJECT IN MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA IN JAPAN

    Nov 1, 2019, 00:00

  • PND53 ECONOMIC EVALUATION OF CLADRIBINE TABLETS IN RELAPSING MULTIPLE SCLEROSIS (RMS) PATIENTS WITH HIGH DISEASE ACTIVITY (HDA) IN LEBANON

    Nov 1, 2019, 00:00

  • PNS289 EVALUATION OF THE SAFETY AND EFFICACY OF AI FOR DETECTION OF CHRONIC NON-COMMUNICABLE DISEASES IN REMOTE AREAS

    Nov 1, 2019, 00:00

  • PDB102 TARGETED LITERATURE REVIEW INTO METHODS OF DETERMINING PATIENTS' PREFERENCE FOR TREATMENT TYPE IN DIABETES

    Nov 1, 2019, 00:00

  • PRO153 PSYCHOMETRIC VALIDATION OF THE PROMIS PHYSICAL FUNCTION MOBILITY, PAIN INTERFERENCE AND FATIGUE IN A COHORT OF PAEDIATRIC X-LINKED HYPOPHOSPHATEMIA (XLH) PATIENTS

    Nov 1, 2019, 00:00

  • PNS145 THE MALTESE EXCEPTIONAL MEDICINAL TREATMENT ROUTE: A BYPASS TO HEALTHCARE?

    Nov 1, 2019, 00:00

  • PCV21 TIMI RISK SCORE IN PREDICTING IN HOSPITAL AND EARLY MORTALITY AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN ELDERLY WOMEN:RESULTS FROM A DEVELOPING COUNTRY

    Nov 1, 2019, 00:00

  • PNS365 THE ADDED VALUE OF USE OF PATIENT PREFERENCE STUDIES IN POLICY DECISION-MAKING: A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN328 CHANGING EPIDEMIOLOGY AND TREATMENT ALGORITHM IN PANCREATIC CANCER IN GERMANY 2017-2018

    Nov 1, 2019, 00:00

  • PDB49 THE RELATIONSHIP BETWEEN HBA1C REDUCTION AND COSTS: A COHORT STUDY OF PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2019, 00:00

  • PDG54 INTERNATIONAL COMPARISON OF ORPHAN DRUG POLICY EFFECT ON ORPHAN DRUG EXPENDITURE

    Nov 1, 2019, 00:00

  • PBI75 REVIEW OF ECONOMIC EVALUATIONS FOR GENE THERAPIES:ARE WE READY FOR THE FUTURE?

    Nov 1, 2019, 00:00

  • PDB100 EXAMINING THE TEMPORAL TRENDS IN HYPOGLYCEMIA EVENTS, TREATMENT ADHERENCE AND A1C IN PATIENTS WITH T2D IN THE US

    Nov 1, 2019, 00:00

  • PCN203 HEALTH-CARE RESOURCE USE AND COSTS IN AML-PATIENTS UNDERGOING STEM CELL TRANSPLANTATION

    Nov 1, 2019, 00:00

  • PCN423 MEASURING FATIGUE SYMPTOMS AND IMPACTS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): EVALUATING DIMENSIONALITY OF THE FACIT-FATIGUE

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PCN227 A PARTITIONED SURVIVAL MODEL TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER

    Nov 1, 2019, 00:00

  • PNS58 ANALYSIS OF FINANCIAL STATUS AND DETERMINANTS WITH ALTMAN'S Z-SCORE MODEL: A PANEL DATA INVESTIGATION FROM TRADITIONAL CHINESE MEDICINE LISTED COMPANIES IN CHINA

    Nov 1, 2019, 00:00

  • PMD3 RETROSPECTIVE ANALYSIS OF OXIDIZED ZIRCONIUM BEARING SURFACE IN HIP REPLACEMENT 90-DAY EPISODE CLAIMS

    Nov 1, 2019, 00:00

  • CP3 DEVELOPING PROCESSES AND METHODS FOR A EUROPEAN COLLABORATION ON HTA: ACHIEVEMENTS, CHALLENGES AND LESSONS LEARNT

    Nov 1, 2019, 00:00

  • PCN426 WHEN CROSS-OVER ISN'T CROSS OVER. STRATEGIES FOR HANDLING EFFECTIVE SUBSEQUENT THERAPIES IN ECONOMIC ANALYSIS OF ONCOLOGY TRIALS

    Nov 1, 2019, 00:00

  • PSU18 THE COST-EFFECTIVENESS OF ENOXAPARIN IN THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING MAJOR SURGERY IN EGYPT

    Nov 1, 2019, 00:00

  • PNS11 EARLY HEALTH ECONOMIC MODELLING AS A TOOL TO GUIDE STRATEGIC CLINICAL DEVELOPMENT AND IN-LICENSING DECISIONS

    Nov 1, 2019, 00:00

  • PNS218 SHAPING THE FUTURE OF EUROPEAN HEALTH TECHNOLOGY ASSESSMENTS: ESTABLISHING A EUROPEAN PICO

    Nov 1, 2019, 00:00

  • PDB124 BURDEN OF HEART FAILURE IN PATIENTS WITH DIABETES IN ENGLAND

    Nov 1, 2019, 00:00

  • PMU13 COST-EFFECTIVENESS ANALYSIS OF PCT-GUIDED ANTIBIOTIC STEWARDSHIP FOR HOSPITALIZED PATIENTS WITH SEPSIS OR LOWER RESPIRATORY TRACT INFECTIONS IN A US HOSPITAL

    Nov 1, 2019, 00:00

  • PDB10 COST ASSOCIATED WITH UNCONTROLLED TYPE 2 DIABETES MELLITUS IN TWO TERTIARY HEALTHCARE FACILITIES IN A RESOURCE-LIMITED SETTING

    Nov 1, 2019, 00:00

  • PMS13 EXPERIMENTAL STUDY OF TOPICAL TREATMENT OF RHEUMATOID ARTHRITIS WITH TNF-Α ANTAGONIST

    Nov 1, 2019, 00:00

  • PCN468 SYSTEMATIC REVIEW OF UTILITY ESTIMATES IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PND125 PREGABALIN PRESCRIBING IN PRIVATE HEALTHCARE SETTINGS IN SOUTH AFRICA WITH SPECIFIC FOCUS ON DOSAGES

    Nov 1, 2019, 00:00

  • PCV87 A REVIEW ASSESSING THE PROPORTION OF HEART FAILURE WITH PRESERVED EJECTION FRACTION PATIENTS AMONGST HEART FAILURE PATIENTS

    Nov 1, 2019, 00:00

  • PCN51 OUTCOMES MANAGEMENT IN A REAL WORLD EVIDENCE CONTEXT. THE CASE OF ABIRATERONE AND ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

    Nov 1, 2019, 00:00

  • PNS319 USE OF ARTIFICIAL INTELLIGENCE WITH DISTILLERSR SOFTWARE AS A REVIEWER FOR A SYSTEMATIC LITERATURE REVIEW OF COST-EFFECTIVENESS MODELS

    Nov 1, 2019, 00:00

  • PCN118 DIRECT MEDICAL COSTS OF THE TREATMENT OF RECTAL CANCER: A REVIEW AND SYNTHESIS OF THE PUBLISHED EVIDENCE

    Nov 1, 2019, 00:00

  • PCN412 COMPARING THE LONG-TERM SURVIVAL METHODOLOGIES IN PHARMACOECONOMIC MODELS OR GLIOBLASTOMA: WHICH BEST REFLECT REAL-WORLD OUTCOMES?

    Nov 1, 2019, 00:00

  • PRS72 DRUG TREATMENT PATTERNS FOR PULMONARY ARTERIAL HYPERTENSION PATIENTS IN ENGLAND: A RETROSPECTIVE ANALYSIS USING HOSPITAL TREATMENT INSIGHTS DATABASE

    Nov 1, 2019, 00:00

  • RARE Process of Care

    Nov 1, 2019, 00:00

  • PIN136 MODELLING CD4 TRANSITIONS IN HIV PATIENTS: VALIDATING A MARKOV MODEL BASED APPROACH

    Nov 1, 2019, 00:00

  • PIN94 HUMAN PAPILLOMAVIRUS (HPV) VACCINE COVERAGE RATES (VCR) IN FRANCE: A FRENCH CLAIMS DATA STUDY

    Nov 1, 2019, 00:00

  • The Joint Committee on Vaccination and Immunisation’s Advice on Extending Human Papillomavirus Vaccination to Boys: Were Cost-Effectiveness Analysis Guidelines Bent to Achieve a Politically Acceptable Decision?

    Nov 1, 2019, 00:00

  • Multiple Diseases - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PUK10 BUDGET IMPACT ANALYSIS OF DEGARELIX FOR THE TREATMENT OF PROSTATE CANCER IN CHINA

    Nov 1, 2019, 00:00

  • PDB131 THE REAL-WORLD DOSE DIFFERENCES OF INSULIN GLARGINE 300 U/ML IN FINLAND

    Nov 1, 2019, 00:00

  • PDB109 BURDEN OF ILLNESS ASSOCIATED WITH HYPERPHAGIA AND SEVERE OBESITY

    Nov 1, 2019, 00:00

  • PMS16 EFFECTS OF HYDROXYCHLOROQUINE ON THROMBOSIS FACTORS AND INFLAMMATORY CYTOKINES IN PATIENTS WITH ELDERLY RHEUMATOID ARTHRITIS

    Nov 1, 2019, 00:00

  • PMS23 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE ANKLE AND FOOT IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PCN9 TREATMENT PATTERNS AND SURVIVAL IN UNRESECTABLE ADVANCED ESOPHAGEAL SQUAMOUS CELL CANCER IN THE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) MEDICARE LINKED DATA

    Nov 1, 2019, 00:00

  • PSU16 ESTIMATING THE CLINICAL AND ECONOMIC IMPACT OF IMPLEMENTING PREOPERATIVE ANEMIA MEASURES IN THE GERMAN HEALTHCARE SYSTEM: THE HEALTH ECONOMIC FOOTPRINT OF PATIENT BLOOD MANAGEMENT (PBM)

    Nov 1, 2019, 00:00

  • PNS206 AIM FOR THE STARS, REACH THE MOON? A SIMPLE STRATEGY TO IMPROVE ADDITIONAL BENEFIT OUCTOMES IN GERMANY?

    Nov 1, 2019, 00:00

  • PNS336 NETWORK META-ANALYSIS (NMA) WITH TIME-VARYING HAZARD: A COMPARATIVE ANALYSIS OF SURVIVAL OUTCOMES

    Nov 1, 2019, 00:00

  • PRO128 AN EVIDENCE-BASED APPROACH TO PREDICT LONG-TERM PATIENT OUTCOMES IN PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME

    Nov 1, 2019, 00:00

  • PCN421 STABILITY OF LIFETIME OVERALL SURVIVAL ESTIMATES OF NIVOLUMAB+IPILIMUMAB IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA

    Nov 1, 2019, 00:00

  • PDG47 STATUS QUO OF PHARMACEUTICAL CARE SYSTEM IN PRIMARY HEALTH CARE INSTITUTIONS OF CHINA——A LARGE SAMPLE SURVEY ON PRIMARY HEALTH CARE INSTITUTIONS OF JANGSU PROVINCE

    Nov 1, 2019, 00:00

  • PIN57 ECONOMIC EVALUATION OF AN ELECTRONIC HEALTH RECORD ALERT BY AGE IN PRIMARY CARE FOR THE DETECTION OF PATIENTS WITH CHRONIC HEPATITIS C

    Nov 1, 2019, 00:00

  • Neurological Disorders - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PCN269 INCIDENCE OF FECAL AND URINARY INCONTINENCE IN PATIENTS WITH A DIAGNOSIS OF RECTAL CARCINOMA

    Nov 1, 2019, 00:00

  • PUK29 DEVELOPING A MAPPING ALGORITHM TO PREDICT EQ-5D VALUES FROM SYMPTOM SCALES IN PATIENTS WITH BLADDER PAIN SYNDROME

    Nov 1, 2019, 00:00

  • PIN113 EU MARKET ACCESS PATHWAYS FOR VACCINES: DEFINITION OF COUNTRY ARCHETYPES USING MATHEMATICAL CLUSTERING

    Nov 1, 2019, 00:00

  • PSY16 COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS TREATMENT IN SPAIN

    Nov 1, 2019, 00:00

  • PRO143 PSYCHOMETRIC EVALUATION OF THE ADVANCED SYSTEMIC MASTOCYTOSIS SYMPTOM ASSESSMENT FORM (ADVSM-SAF) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS

    Nov 1, 2019, 00:00

  • PRS65 BEVACIZUMAB INDUCED PULMONARY EMBOLISM: A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE

    Nov 1, 2019, 00:00

  • PND133 IMPACT OF CLINICAL COMPLICATIONS ON ECONOMIC BURDEN IN NEWLY DIAGNOSED PARKINSON POPULATION USING A US CLAIM DATABASE

    Nov 1, 2019, 00:00

  • PDG99 PATIENT'S PREFERENCES REGARDING DIRECT ORAL ANTICOAGULANTS SELECTION: RELEVANT CRITERIA FOR ROUTINE CLINICAL DECISION MAKING?

    Nov 1, 2019, 00:00

  • PRO71 WHAT WAS THE ACTUAL BUDGET IMPACT OF ORPHAN MEDICINAL PRODUCTS BETWEEN 2000-2017 IN EUROPE?

    Nov 1, 2019, 00:00

  • PCN499 REAL WORLD TREATMENT AND SURVIVAL OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: AN ANALYSIS USING JAPANESE CLAIMS DATA

    Nov 1, 2019, 00:00

  • PNS97 GEOGRAPHIC DIFFERENCES IN IRISH HEALTH STATUS

    Nov 1, 2019, 00:00

  • PIN80 CEFTAZIDIME-AVIBACTAM FOR THE TREATMENT OF CARBAPENEM-RESISTANT PATHOGENS ASSOCIATED WITH HEALTHCARE-ASSOSIATED INFECTIONS: A BUDGET IMPACT ANALYSIS IN ARGENTINA

    Nov 1, 2019, 00:00

  • PRS25 THE IMPACT TRIAL: IS SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) COST-EFFECTIVE VERSUS DUAL THERAPY WITH INHALED CORTICOSTEROID PLUS LONG-ACTING BETA AGONIST (FF/VI) IN PATIENTS WITH COPD IN SPAIN?

    Nov 1, 2019, 00:00

  • PCN78 CHANGES IN HEALTH STATE COSTS IN HEPATOCELLULAR CARCINOMA (HCC)

    Nov 1, 2019, 00:00

  • PNS332 DEALING WITH MISSING DATA IN TRIAL-BASED ECONOMIC EVALUATIONS: A METHODOLOGICAL SCOPING REVIEW

    Nov 1, 2019, 00:00

  • PCN358 COMPARING AND VALIDATING THE OVERALL SURVIVAL EXTRAPOLATIONS FOR IMMUNO-ONCOLOGY TREATMENTS APPLIED IN HTA'S BY NOMA AND TLV

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCV154 A NOVEL PREDICTION FOR ADVERSE CARDIAC EVENTS IN PATIENTS WITH NON-OBSTRUCTIVE CORONARY ARTERY DISEASE

    Nov 1, 2019, 00:00

  • PDB129 PRIMARY AND SECONDARY HEALTHCARE RESOURCE USE AND ASSOCIATED COSTS IN PEOPLE WITH HEPATIC ENCEPHALOPATHY IN ENGLAND

    Nov 1, 2019, 00:00

  • PCN278 EXPLORING PRE AND POST AGENZIA ITALIANA DEL FARMACO (AIFA) REIMBURSED ACCESS TO IMMUNOTHERAPY FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

    Nov 1, 2019, 00:00

  • PMH69 RISING DEPENDENCE ON ANTI-DEPRESSANTS AMONG ADULTS IN US: A STUDY BASED ON NHANES FROM 2005 TO 2016

    Nov 1, 2019, 00:00

  • RW2 METHODOLOGICAL APPROACHES FOR INCORPORATING REAL-WORLD DATA (RWD) FOR OVERALL SURVIVAL (OS) INTO LONG-TERM SURVIVAL ESTIMATES: A CASE-STUDY NICE TECHNOLOGY APPRAISAL IN EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC)

    Nov 1, 2019, 00:00

  • PNS115 BARRIERS TO TRANSPARENCY IMPROVEMENT OF HOSPITALS PERFORMANCE: A QUALITATIVE STUDY IN IRAN

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Clinical Outcomes

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Organizational Practices

    Nov 1, 2019, 00:00

  • PNS401 THE FIRST PARALLEL EQ-5D-3L AND EQ-5D-5L COMPOSITE TIME TRADE-OFF VALUATION STUDY IN EUROPE

    Nov 1, 2019, 00:00

  • PDB97 THE EFFECT OF NIGHT EATING ON NUTRITIONAL HABITS AND QUALITY OF LIFE OF DIABETIC PATIENTS

    Nov 1, 2019, 00:00

  • PDB56 ECONOMIC IMPACT OF TYPE 2 DIABETES AND DIABETES-ASSOCIATED COMPLICATIONS: A LARGE CLAIMS-BASED STUDY

    Nov 1, 2019, 00:00

  • PCN177 ORGANIZATIONAL AND ECONOMIC IMPACT OF NEXT GENERATION SEQUENCING AND HOTSPOT APPROACH

    Nov 1, 2019, 00:00

  • PMU108 LEVERAGING ELECTRONIC HEALTH RECORDS TO MEET THE REAL-WORLD EVIDENCE NEEDS OF HTA: A UK PERSPECTIVE

    Nov 1, 2019, 00:00

  • PND11 IMPACT OF A COMMUNITY PHARMACY-BASED INFORMATION PROTOCOL ON MULTIPLE SCLEROSIS PATIENTS' ADHERENCE TO THEIR ORAL TREATMENT WITH DIMETHYL FUMARATE: TECPHIE, A RANDOMIZED STUDY VS USUAL PRACTICE (INTERIM RESULTS)

    Nov 1, 2019, 00:00

  • PCN205 COMPARISON OF METHODS TO ACCOUNT FOR CURED PATIENTS IN A COST-EFFECTIVENESS ANALYSIS: A CASE STUDY IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PCN268 ESTIMATING THE BURDEN OF MALIGNANT HAEMATOPOIETIC CANCERS IN NORDIC COUNTRIES: A PREDICTIVE ANALYSIS USING TIME SERIES ANALYSIS METHODS

    Nov 1, 2019, 00:00

  • PIH11 ECONOMIC EVALUATION OF OSPEMIFENE FOR THE TREATMENT OF VULVOVAGINAL ATROPHY IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PCN438 ECONOMIC EVALUATION METHODS IN ONCOLOGY: ONWARDS AND UPWARDS

    Nov 1, 2019, 00:00

  • PNS236 COMPARATIVE ANALYSIS OF TRANSPARENCY COMMITTEE OPINION CONCERNING THE MEDICAL BENEFIT OBTAINED BY DRUGS AVAILABLE IN EARLY ACCESS PROGRAM VS THE OTHERS IN FRANCE

    Nov 1, 2019, 00:00

  • PCV37 BUDGET IMPACT ANALYSIS OF ANTIPLATELET THERAPY WITH CANGRELOR IN PATIENTS WITH ACUTE CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN SPAIN

    Nov 1, 2019, 00:00

  • PNS316 USE OF GENERALISED FLUCTUATION TEST TO OPTIMISE PIECEWISE FITTING IN IMMUNO-ONCOLOGY (IO) SURVIVAL MODELLING

    Nov 1, 2019, 00:00

  • PDB44 COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS LASER PHOTOCOAGULATION AND RANIBIZUMAB IN THE TREATMENT OF VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA IN CHINA

    Nov 1, 2019, 00:00

  • PNS61 DOES A STANDARD WILLINGNESS-TO-PAY THRESHOLD EXIST IN GREECE?

    Nov 1, 2019, 00:00

  • PSS22 FACTORS INFLUENCING AGREEMENT BETWEEN PATIENT AND CLINICIAN ASSESSMENTS OF SEVERITY IN CHRONIC PLAQUE PSORIASIS

    Nov 1, 2019, 00:00

  • PMU131 VALIDITY OF THE POLISH VERSION OF THE CARERQOL-7D QUESTIONNAIRE AMONG INFORMAL CAREGIVERS IN THE POLISH GENERAL POPULATION

    Nov 1, 2019, 00:00

  • PCN281 IDENTIFYING THE KEY CHALLENGES IN EVALUATION AND PRICING OF ONCOLOGY COMBINATION THERAPIES AND FUTURE POLICY CHANGES USING A WEB-BASED PORTAL TO ENGAGE PAYERS

    Nov 1, 2019, 00:00

  • PMU148 CUTANEOUS LYMPHOMAS IN GERMANY: LANDSCAPING ANALYSIS OF GERMAN STATUTORY HEALTH INSURANCE (SHI) CLAIMS DATA

    Nov 1, 2019, 00:00

  • PBI8 UNKNOWN

    Nov 1, 2019, 00:00

  • PBI26 THE ECONOMIC REASON FOR THE USE OF VEDOLIZUMAB COMPARED WITH INHIBITORS OF TNF-ALPHA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON THE EXAMPLE OF MOSCOW

    Nov 1, 2019, 00:00

  • PCV105 A SCOPING REVIEW OF INTERNATIONAL MODELS OF ADULT SPECIALIST CARDIAC NETWORKS

    Nov 1, 2019, 00:00

  • PNS173 MEASURING DELAYS IN THE AVAILABILITY OF NEW MEDICINES WITHIN EUROPE USING A TIME-TO-PRICE INDICATOR

    Nov 1, 2019, 00:00

  • PSU10 ECONOMIC EVALUATION OF HYSTERECTOMY IN THE REAL CLINICAL PRACTICE: ROBOT-ASSISTED VERSUS CONVENTIONAL LAPAROSCOPIC

    Nov 1, 2019, 00:00

  • PMS43 DUCHENNE MUSCULAR DYSTROPHY PREVALENCE IN FIVE EUROPEAN COUNTRIES: A NOVEL INCIDENCE-BASED MODELING APPROACH USING SYSTEM DYNAMICS

    Nov 1, 2019, 00:00

  • PNS204 THE RELEVANCE OF REAL WORLD EVIDENCE STUDIES IN THE GERMAN BENEFIT ASSESSMENT (AMNOG) PROCESS

    Nov 1, 2019, 00:00

  • PNS21 REAL WORLD EVIDENCE (RWE) IN PARTITION SURVIVAL MODELLING: IS IT THE REAL DEAL?

    Nov 1, 2019, 00:00

  • PCN48 FEASIBILITY OF EXTRACTING SURVIVAL DATA FROM PUBLISHED LITERATURE USING THE GUYOT ALGORITHM

    Nov 1, 2019, 00:00

  • PCN60 VALUE OF NEOADJUVANT IO THERAPIES WITH OR WITHOUT ADJUVANT CANCER THERAPIES: A MODEL FRAMEWORK

    Nov 1, 2019, 00:00

  • PDG109 REPLACING BRANDED ANTINEOPLASTIC DRUGS WITH GENERICS OR BIOSIMILARS: FORCAST OF BUDGET SAVINGS FOR THE PERSPECTIVE PERIOD

    Nov 1, 2019, 00:00

  • RARE Regulatory

    Nov 1, 2019, 00:00

  • PCN26 QUANTIFYING THE RELATIVE CLINICAL VALUE OF NIVOLUMAB PLUS IPILIMUMAB VS. SUNITINIB IN FIRST-LINE ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH THE NUMBER NEEDED TO TREAT AND NUMBER NEEDED TO HARM IN SPAIN AND PORTUGAL

    Nov 1, 2019, 00:00

  • PMU85 LESSONS FOR BREAKING NEW GROUND WITH FIRST-IN-CLASS THERAPIES

    Nov 1, 2019, 00:00

  • PND75 VALIDATION OF AN ALGORITHM IDENTIFYING RELAPSES IN MULTIPLE SCLEROSIS USING THE FRENCH NATIONWIDE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PUK18 THE ECONOMIC COST ASSOCIATED WITH NOCTURIA IN A WORKING-AGE POPULATION

    Nov 1, 2019, 00:00

  • PNS323 WHAT IS A VALID MAPPING ALGORISM IN COST-UTILITY ANALYSES? AN ANSWER FROM A MISSING DATA PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN200 REAL-WORLD HEALTHCARE RESOURCE UTILIZATION IN PATIENTS SUFFERING FROM MALIGNANT MELANOMA, A FINNISH REGISTRY STUDY

    Nov 1, 2019, 00:00

  • PMU22 BROADER ECONOMIC BURDEN OF SMOKING ATTRIBUTABLE DISEASES IN GREECE

    Nov 1, 2019, 00:00

  • PNS163 SHIFTING PARADIGM OF INTERNATIONAL REFERENCE PRICING. IS IT BENEFICIAL TO PAYERS, MANUFACTURERS OR PATIENTS?

    Nov 1, 2019, 00:00

  • PBI13 TNF-ALPHA INHIBITORS IN THE CZECH REPUBLIC: HOW BIOSIMILARS AFFECT OVERALL CONSUMPTION AND COSTS?

    Nov 1, 2019, 00:00

  • PDB61 THE CLINICAL AND ECONOMIC IMPACT OF ADDING AN ADHERENCE MODULE TO THE IQVIA CORE DIABETES MODEL

    Nov 1, 2019, 00:00

  • PIN35 GLOBAL ANNUAL COSTS OF PEOPLE LIVING WITH HIV IN FRANCE IN 2013 FROM A NATIONAL INSURANCE CLAIMS DATABASE (SNIIRAM)

    Nov 1, 2019, 00:00

  • PGI32 EVALUATION OF THE COST-UTILITY OF THE YORK FAECAL CALPROTECTIN CARE PATHWAY

    Nov 1, 2019, 00:00

  • PND7 EFFICACY OF VIRTUAL REALITY GLASSES AMONG PATIENTS WITH STROKE

    Nov 1, 2019, 00:00

  • PRS41 IDENTIFICATION OF POTENTIALLY UNDIAGNOSED PATIENTS WITH NON-TUBERCULOUS MYCOBACTERIAL LUNG DISEASE USING MACHINE LEARNING APPLIED TO PRIMARY CARE DATA IN UK

    Nov 1, 2019, 00:00

  • PCN394 DETERMINANTS OF MANAGED ENTRY AGREEMENTS IN THE CONTEXT OF HTA; EMPIRICAL EVIDENCE FROM ONCOLOGY MEDICINES IN FOUR COUNTRIES.

    Nov 1, 2019, 00:00

  • PMD14 COST-EFFECTIVENESS ANALYSIS OF THE USE OF MICROINVASIVE SURGERY WITH ISTENT® IN COMBINATION WITH PHACOEMUSIFICATION FOR GLAUCOMA AND CATARACT PATIENTS IN THE MEXICAN PUBLIC HEALTH SYSTEM.

    Nov 1, 2019, 00:00

  • Infectious Disease Studies

    Nov 1, 2019, 00:00

  • PGI51 PSYCHOMETRIC EVALUATION OF NASH-CHECK, A PATIENT-REPORTED OUTCOME MEASURE FOR NONALCOHOLIC STEATOHEPATITIS

    Nov 1, 2019, 00:00

  • PNS51 SHIFTING THE MARKET ACCESS FRAMEWORK TO INVESTMENT DECISIONS IN EARLY ASSETS

    Nov 1, 2019, 00:00

  • PRO35 ANALYZING THE LEVEL OF EVIDENCE REQUIRED FOR ONCOLOGY VERSUS NON-ONCOLOGY ORPHAN DRUGS AS IT RELATES TO PRICE

    Nov 1, 2019, 00:00

  • PNS309 UTILIZING MACHINE LEARNING AND ECG DATA FOR CONTINUOUS USER AUTHENTICATION OF PATIENTS DURING A CLINICAL TRIAL

    Nov 1, 2019, 00:00

  • PSS4 COST-EFFECTIVENESS ANALYSIS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION (CNV) IN CHINA

    Nov 1, 2019, 00:00

  • PCV134 MOBILE HEALTH TECHNOLOGY PERCEPTIONS AND USER EXPERIENCE AMONG ATRIAL FIBRILLATION PATIENTS: A SOCIAL MEDIA LISTENING STUDY

    Nov 1, 2019, 00:00

  • PNS177 BARRIERS TO PUBLIC PRIVATE PARTNERSHIPS IMPLEMENTATION IN HEALTHCARE SECTOR IN KINGDOM OF SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PCN337 HTA DECISIONS IN FRANCE AND GERMANY: LESSONS FROM MELANOMA

    Nov 1, 2019, 00:00

  • PMH34 THE ECONOMIC BURDEN OF SCHIZOPHRENIA: A REAL-WORLD DATA ANALYSIS IN ITALY

    Nov 1, 2019, 00:00

  • PRO74 TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5 IN THE LAST THREE YEARS

    Nov 1, 2019, 00:00

  • PND79 HOW DIFFERENT ARE MIGRAINE PATIENTS TREATED BY GENERAL PRACTITIONERS VERSUS THOSE TREATED BY NEUROLOGISTS?

    Nov 1, 2019, 00:00

  • PMU61 IDENTIFYING DISEASE AREAS WHERE DISRUPTIVE INNOVATION IS LIKELY TO HAVE A SIGNIFICANT IMPACT ON HEALTHCARE SYSTEMS AND BUDGETS. THE IMPORTANCE OF TRACKING PAYER BEHAVIOURS

    Nov 1, 2019, 00:00

  • PCN410 USE OF EXTERNAL INFORMATION FROM HISTORICAL TRIAL DATA TO IMPROVE SURVIVAL ESTIMATIONS ON IMMATURE SURVIVAL DATA IN MULTIPLE MYELOMA (MM)

    Nov 1, 2019, 00:00

  • PCN127 NUMBER NEEDED TO TREAT (NNT) AND COST OF PREVENTING AN EVENT (COPE) COMPARISON BETWEEN THE TRIPLETS DRD AND KRD FOR RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA IN THE BRAZILIAN PRIVATE SYSTEM

    Nov 1, 2019, 00:00

  • PCN516 EXPLORING THE CURRENT STATUS OF NEUROENDOCRINE TUMOURS: A POPULATION-BASED ANALYSIS OF EPIDEMIOLOGY, MANAGEMENT AND USE OF RESOURCES

    Nov 1, 2019, 00:00

  • PBI46 IMPLEMENTATION OF ADALIMUMAB BIOSIMILARS IN DENMARK

    Nov 1, 2019, 00:00

  • PSY40 ASSESSING THE QUALITY AND COHERENCE OF NETWORK META-ANALYSES OF BIOLOGICS IN PLAQUE PSORIASIS: WHAT DOES ALL THIS EVIDENCE SYNTHESIS TELL US?

    Nov 1, 2019, 00:00

  • RE3 A PROPOSED, SCALABLE APPROACH TO IMPLEMENTING INNOVATIVE PAYMENT AGREEMENTS

    Nov 1, 2019, 00:00

  • PNS137 ORPHAN DRUGS: WHAT FACTORS IMPACT THE PRICE IN FRANCE?

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PNS358 DEVELOPMENT AND OPTIMIZATION OF NATIONWIDE INTEROPERABLE CLINICAL TRIAL MANAGEMENT SYSTEM (CTMS) IN KOREA

    Nov 1, 2019, 00:00

  • PNS262 EARLY DIALOGUE WITH NICE AND EUNETHTA: A UK PERSPECTIVE IN A POLITICALLY UNCERTAIN ERA

    Nov 1, 2019, 00:00

  • PSY25 THE RELATIONSHIP BETWEEN PEANUT ALLERGY PREVALENCE AND THE DIFFERENT DIAGNOSTIC METHODS USED, ACROSS 5 EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PCN368 ADVANCED NMA TECHNIQUES IN NICE STA SUBMISSIONS

    Nov 1, 2019, 00:00

  • PSU27 ANALYSIS OF THE UTILIZATION OF ONE-DAY SURGERY AMONG CASES RELATED TO THE DISEASES OF THE MUSCULOSKELETAL SYSTEM OR CONNECTIVE TISSUE

    Nov 1, 2019, 00:00

  • PCV125 DIFFERENCES ACROSS HEART FAILURE PATIENTS' CHARACTERISTICS, DISEASE EXPERIENCE AND QUALITY OF LIFE IN SHANGHAI COMPARED WITH REST OF CHINA

    Nov 1, 2019, 00:00

  • PND106 LIVING WITH MIGRAINE: SUPPORT NEEDED AND HEALTHCARE EXPENDITURE ON BRAZILIAN PATIENTS FROM THE MY MIGRAINE VOICE SURVEY

    Nov 1, 2019, 00:00

  • PBI63 IMPACT OF TOCILIZUMAB SUBCUTANEOUS INJECTION COMMERCIALIZATION ON PRACTICES IN THE PUBLIC HOSPITALS OF PARIS

    Nov 1, 2019, 00:00

  • PRO161 EPIDEMIOLOGY, HEALTHCARE RESOURCE CONSUMPTION AND RELATED COSTS FOR HYPOPHOSPHATEMIC VITAMIN D RESISTANT RICKETS PATIENTS IN AN ITALIAN REGION

    Nov 1, 2019, 00:00

  • PRO55 COST-EFFECTIVENESS ANALYSIS OF PIRFENIDONE TABLETS COMPARED WITH NINTEDANIB FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) TREATMENT IN TURKEY

    Nov 1, 2019, 00:00

  • PDG31 COST-EFFECTIVENESS OF RANIBIZUMAB VERSUS LASER PHOTOCOAGULATION OR OBSERVATION FOR THE TREATMENT OF MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION: FROM CHINESE SOCIETAL PERSPECTIVE

    Nov 1, 2019, 00:00

  • PMU33 EPIDEMIOLOGY OF PROLIFERATIVE DIABETIC RETINOPATHY (PDR): EVIDENCE FROM A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PIT5 EXPERIENCE OF 2 INSTITUTIONS WITH THE GERIATRIC FRACTURE PROGRAM IN COLOMBIA: LENGTH OF STAY, MORTALITY AND ESTIMATION OF COSTS

    Nov 1, 2019, 00:00

  • PMU46 POSITIVE IMPACT OF INNOVATIVE STATUS IN PR PROCESS TIMING IN ITALY

    Nov 1, 2019, 00:00

  • PNS364 PATIENT INVOLVEMENT IN EUNETHTA PHARMACEUTICAL JOINT CLINICAL ASSESSMENTS

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00
  • «
  • 41
  • 42
  • 43
  • 44
  • 45 (current)
  • 46
  • 47
  • 48
  • 49
  • 50
  • »